You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Details for Patent: 8,865,698


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,865,698
Title:Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Abstract: Provided herein are methods for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal, which comprises administering to said mammal in need thereof a therapeutically effective amount of a compound of Formula I: ##STR00001## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, X, Y and n have the meanings given in the specification.
Inventor(s): Haas; Julia (Boulder, CO), Andrews; Steven W. (Boulder, CO), Jiang; Yutong (Boulder, CO), Zhang; Gan (Niwot, CO)
Assignee: Array BioPharma Inc. (Boulder, CO)
Application Number:13/943,590
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 8,865,698

Introduction

United States Patent 8,865,698, titled "Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds," is a patent that protects a specific method of treatment using particular chemical compounds. To understand the scope and claims of this patent, it is essential to delve into its details, the patenting process, and the broader context of intellectual property protection.

Patent Overview

Invention and Inventorship

The patent in question involves a method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds. Under U.S. patent law, the inventors of such patentable subject matter must be correctly identified. The process of determining inventorship involves two key steps: the conception of the idea and the reduction of the idea to practice[2].

Patent Claims

The patent claims are the heart of any patent application, defining the scope of the invention. For US-8865698-B2, the claims specify the method of treatment, including the types of compounds used and the conditions under which they are applied. The Patent Claims Research Dataset by the USPTO provides detailed information on claims from U.S. patents, including claim-level statistics and document-level statistics, which can be useful in understanding the scope of patent claims[3].

Scope of the Patent

Claims Analysis

The scope of the patent is defined by its claims, which must be novel, nonobvious, and enabled. For US-8865698-B2, the claims would detail the specific chemical structures of the substituted pyrazolo[1,5-a]pyrimidine compounds and the methods by which they are used for treatment. This specificity is crucial in distinguishing the invention from prior art and ensuring that the patent is upheld if challenged.

Enablement and Written Description

The patent must also meet the requirements of enablement and written description. This means that the patent application must teach a person with ordinary skill in the art how to make and use the invention. The enablement requirement ensures that the invention is not merely theoretical but can be practically implemented[5].

Patent Landscape

Prior Art and Novelty

To be patentable, the invention must be novel and nonobvious over the prior art. The patent landscape for US-8865698-B2 would involve an analysis of existing patents and publications related to pyrazolo[1,5-a]pyrimidine compounds and their use in treatment methods. This analysis helps in understanding how the patented method differs from existing knowledge and ensures that it does not infringe on other patents[5].

Competitors and Market Impact

The patent landscape also includes an assessment of competitors and the potential market impact of the patented invention. Understanding who else is working in this field and the commercial value of the invention is crucial for strategic decision-making. For instance, if the invention has high commercial value, it may warrant international patent protection through a Patent Cooperation Treaty (PCT) application[5].

Patent Quality and Examination

USPTO's Enhanced Patent Quality Initiative

The USPTO has implemented various initiatives to improve patent quality, including the Enhanced Patent Quality Initiative. This initiative aims to ensure that patents are correctly issued in compliance with all statutory requirements. For patents like US-8865698-B2, this means that the USPTO would have evaluated the application against criteria such as novelty, nonobviousness, and enablement[1].

Performance Metrics and Correctness Measures

The USPTO uses performance metrics and correctness measures to assess the quality of patent examinations. These measures include statutory compliance rates for different sections of the patent code (e.g., 35 U.S.C. 101, 112, 102, and 103). Ensuring high compliance rates helps in maintaining the integrity of the patent system and the validity of issued patents[1].

Patent Prosecution Process

Filing and Examination

The patent prosecution process for US-8865698-B2 would have involved filing a provisional patent application followed by a non-provisional application. The USPTO would then examine the application to determine if the claimed invention meets the statutory requirements. This process can be complex and may involve multiple rounds of arguments and amended claims[5].

Appeals and Final Rejection

If the patent examiner does not accept the arguments or amended claims, the application may be subject to a final rejection. In such cases, the applicant can appeal to the Patent Trial and Appeal Board (PTAB) or the U.S. court system. The success of the appeal determines whether the patent will be granted[5].

Cost and Commercial Considerations

Financial Implications

Obtaining and maintaining a patent can be costly. The process of drafting and filing a non-provisional patent application can cost between $8,000 and $20,000, with additional costs incurred during the prosecution process and after the patent is issued. For international patents, the costs can be significantly higher[5].

Commercial Partners and Licensing

Often, commercial partners play a crucial role in covering these costs, especially if the invention has significant commercial value. Early identification of a commercial partner can help in offsetting the financial burden of patenting and commercializing the invention[5].

Key Takeaways

  • Inventorship and Conception: Correctly identifying the inventors is crucial, involving both the conception of the idea and its reduction to practice.
  • Patent Claims: The claims define the scope of the invention and must meet novelty, nonobviousness, and enablement requirements.
  • Patent Quality: The USPTO's Enhanced Patent Quality Initiative ensures that patents are correctly issued and meet statutory requirements.
  • Patent Prosecution: The process involves filing applications, examination, and potential appeals, with significant financial implications.
  • Commercial Value: Early identification of commercial partners can help in covering costs and ensuring the commercial success of the patented invention.

FAQs

Q: What are the key steps in determining inventorship for a U.S. patent application? A: Determining inventorship involves two steps: the conception of the idea and the reduction of the idea to practice[2].

Q: How does the USPTO ensure patent quality? A: The USPTO uses initiatives like the Enhanced Patent Quality Initiative, performance metrics, and correctness measures to ensure patents meet statutory requirements[1].

Q: What is the significance of claim clarity tools in patent applications? A: Claim clarity tools, such as glossaries or claim charts, can help in ensuring that patent claims are clear and specific, although the USPTO has decided not to require these tools after stakeholder feedback[1].

Q: How long does the patent prosecution process typically take? A: The patent prosecution process can take two to five years, depending on the complexity of the invention and the number of rounds of arguments and amended claims[5].

Q: What is the financial impact of obtaining and maintaining a patent? A: The cost of obtaining and maintaining a patent can range from $8,000 to $20,000 for a U.S. non-provisional patent application, with additional costs for international patents and ongoing maintenance[5].

Sources

  1. GAO Report: Intellectual Property: Patent Office Should Define Quality, Reassess Incentives, and Improve Application Review Process. U.S. Government Accountability Office, June 30, 2016.
  2. Oregon State University: Determining Inventorship for US Patent Applications. Agricultural Sciences, Oregon State University.
  3. USPTO: Patent Claims Research Dataset. U.S. Patent and Trademark Office.
  4. PubChem: Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds. National Center for Biotechnology Information.
  5. KU Office of Research: Intellectual Property Protection. University of Kansas Center for Technology Commercialization.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,865,698

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare VITRAKVI larotrectinib sulfate CAPSULE;ORAL 210861-001 Nov 26, 2018 RX Yes No 8,865,698 ⤷  Subscribe METHOD OF TREATING CANCEROUS SOLID TUMORS ⤷  Subscribe
Bayer Hlthcare VITRAKVI larotrectinib sulfate CAPSULE;ORAL 210861-002 Nov 26, 2018 RX Yes Yes 8,865,698 ⤷  Subscribe METHOD OF TREATING CANCEROUS SOLID TUMORS ⤷  Subscribe
Bayer Healthcare VITRAKVI larotrectinib sulfate SOLUTION;ORAL 211710-001 Nov 26, 2018 RX Yes Yes 8,865,698 ⤷  Subscribe METHOD OF TREATING CANCEROUS SOLID TUMORS ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,865,698

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3106463 ⤷  Subscribe 301033 Netherlands ⤷  Subscribe
European Patent Office 3106463 ⤷  Subscribe PA2020504 Lithuania ⤷  Subscribe
European Patent Office 3106463 ⤷  Subscribe CA 2020 00013 Denmark ⤷  Subscribe
European Patent Office 3106463 ⤷  Subscribe 122020000012 Germany ⤷  Subscribe
European Patent Office 3106463 ⤷  Subscribe LUC00150 Luxembourg ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.